First, although short- to mid-term safety data indicate an adequate safety profile, long-term pharmacovigilance is essential to fully assess risks related to sustained GM-CSF suppression, including infection, malignancy, and alterations in tissue homeostasis. This evidence concerns the gene CSF2 and infection.